Effect of Saraswata ghrita on Alzheimers disease

Pharmaceutical Standardization of Saraswata Ghrita and its effect on Alzheimerâ??s Disease (Smritibhramsa) by Oral and Nasal Routes (A Randomized Controlled Clinical Trial)

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/03/024381

Enrollment

Registered

2020-03-31

Start date

Unknown

Completion date

Unknown

Last updated

2023-02-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G309- Alzheimers disease, unspecified

Interventions

Intervention1: saraswata ghrita nasya: Patients will be treated with Nasya (2 Bindu each nostril) of Saraswata Ghrita twice a day along with conventional medicine for 90 days duration Intervention2: s

Eligibility

Inclusion criteria

Inclusion criteria: Diagnosed case of Alzheimerâ??s disease as per DSM-IV criteria.

Exclusion criteria

Exclusion criteria: 1.Patients with any anatomical deformities will be excluded. 2.Patient Ayogya for Nasya karma.

Design outcomes

Primary

Measure	Time frame
The study is anticipated to generate usefulness in improving quality of life of Alzheimerâ??s disease patients. The study would also generate evidence regarding difference in efficacy of Saraswata Ghrita administered through different routesTimepoint: Assesssment at 0 days, 30 days , 60 days and 90 days.	—

Secondary

Measure	Time frame
Secondary: The results will help in estimating the possible mode of efficacy of the trial drug by nasya and oral route as well as generate evidences regarding its usefulness in AD.Timepoint: Duration of trial is 12 weeks and the patients will be followed up every 15th day, for a period of 12 weeks after that follow up will be done after one month of completion of trial to see the recurrence or any type of changes associated with Alzheimerâ??s disease.Assesssment at 0 days, 30 days , 60 days and 90 days.	—

Measure

Time frame

Secondary: The results will help in estimating the possible mode of efficacy of the trial drug by nasya and oral route as well as generate evidences regarding its usefulness in AD.Timepoint: Duration of trial is 12 weeks and the patients will be followed up every 15th day, for a period of 12 weeks after that follow up will be done after one month of completion of trial to see the recurrence or any type of changes associated with Alzheimerâ??s disease.Assesssment at 0 days, 30 days , 60 days and 90 days.

—

Countries

India

Contacts

Public ContactProf P K Prajapati

All India Institute of Ayurveda

prajapati.pradeep1@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026